Cargando…

Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?

Newly diagnosed high grade serous epithelial ovarian cancer (EOC) patients are treated with radical surgery followed by adjuvant platinum and taxane combination chemotherapy. In EOC patients where upfront surgery is contraindicated for medical reasons (e.g., comorbidities or poor performance status)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moschetta, Michele, Boussios, Stergios, Rassy, Elie, Samartzis, Eleftherios P., Funingana, Gabriel, Uccello, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Review Article on Ovarian Cancer: State of the Art and Perspectives of Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812234/ https://www.ncbi.nlm.nih.gov/pubmed/33490222 http://dx.doi.org/10.21037/atm-20-1683

Ejemplares similares

Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches
por: Uccello, Mario, et al.
Publicado: (2020)

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
por: Boussios, Stergios, et al.
Publicado: (2020)

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review
por: Samartzis, Eleftherios P., et al.
Publicado: (2020)

Nature and nurture in neuropsychiatric genetics: where do we stand?
por: Dick, Danielle M., et al.
Publicado: (2010)

Prediction of treatment outcomes in psychiatry—where do we stand ?
por: McMahon, Francis J.
Publicado: (2014)

Immunosuppression in kidney transplant recipients with COVID-19 infection – where do we stand and where are we heading?
por: Daoud, Ahmed, et al.
Publicado: (2021)

The impact of the digital revolution  on human brain and behavior: where  do we stand? 
por: Korte, Martin
Publicado: (2020)

Psychiatric manifestations of neurologic disease: where are we headed?
por: Lyketsos, Constantin G., et al.
Publicado: (2007)

Active surveillance in prostate cancer management: where do we stand now?
por: Dragan, Jędrzej, et al.
Publicado: (2020)

Double or dual stimulation in poor ovarian responders: where do we stand?
por: Polat, Mehtap, et al.
Publicado: (2021)

NOTCH signalling in ovarian cancer angiogenesis
por: Perez-Fidalgo, Jose Alejandro, et al.
Publicado: (2020)

Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered
por: Rassy, Elie, et al.
Publicado: (2020)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Neutrino Masses and Mixing: Where We Stand and Where We are Going
por: Gonzalez-Garcia, M.C.
Publicado: (2002)

Alzheimer’s disease and infections, where we stand and where we go
por: Monastero, Roberto, et al.
Publicado: (2014)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

MicroRNAs and metabolic disorders – where are we heading?
por: Sliwinska, Agnieszka, et al.
Publicado: (2017)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Sympathetic Modulation in Cardiac Arrhythmias: Where We Stand and Where We Go
por: Chung, Wei-Hsin, et al.
Publicado: (2023)

Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
por: Coppola, Alessandro, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?
por: Mitrovic, Bojan, et al.
Publicado: (2022)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?
por: Agapidou, Alexandra, et al.
Publicado: (2016)

Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
por: Laine, Christopher G., et al.
Publicado: (2020)

Late Sodium Current of the Heart: Where Do We Stand and Where Are We Going?
por: Horváth, Balázs, et al.
Publicado: (2022)

Stroke and Bleeding Risk Assessment in Atrial Fibrillation: Where Are We Now?
por: Kuo, Ling, et al.
Publicado: (2021)

Ovarian cancer: state of the art and perspectives of clinical research
por: Boussios, Stergios, et al.
Publicado: (2020)

Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going
por: Risitano, Antonio M
Publicado: (2014)

Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?
por: Banz-Jansen, Constanze, et al.
Publicado: (2022)

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
por: Harari, Sergio, et al.
Publicado: (2015)

Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?
por: Rassy, Elie, et al.
Publicado: (2020)

The Clusmy Child: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2003)

European HEPnet: where we are and where we are going
por: Carpenter, B E, et al.
Publicado: (1990)

Iron health: where are we and where are we going?
por: Gotardo, Glória Ines Beal
Publicado: (2011)

Hip Arthroscopy: Where We Are, and Where We Are Going
por: Park, Myung Sik, et al.
Publicado: (2015)

Bioactive Glasses: Where Are We and Where Are We Going?
por: Baino, Francesco, et al.
Publicado: (2018)

Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017)

Obstetric ultrasound: where are we and where are we going?
por: Abramowicz, Jacques S
Publicado: (2021)

Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d1bkm5u7r00jf3u2vj7l08rqqh